Pharma RSS Digest - 2026-04-28
Overview
The 48-hour window produced a light but substantive pharma tape dominated by Asian-listed biotechs presenting at a major hepatitis conference and advancing metabolic disease programs. Both stories originated from PR Newswire Health, which provided the only surviving wire coverage during this cycle. The market tone is tilted toward conference and platform news, with no broad sector shifts or alert-level events detected. Investors parsing this digest should note the tape is thin—two key developments total with no supplementary watchlist items—making it difficult to draw macro pharma inferences.
Key Developments
Ascletis Completes Enrollment for Oral GLP-1 Agonist Phase II Study
Ascletis Pharma announced completion of enrollment in its 100-participant U.S. Phase II study of ASC30, an oral small molecule GLP-1 receptor agonist for type 2 diabetes. The 13-week trial randomizes participants to placebo, 40mg, 60mg, and 80mg dose arms with weekly titration, using HbA1c change from baseline as the primary endpoint. Prior positive Phase II results for obesity were disclosed in December 2025, and the company expects topline data for the diabetes indication in Q3 2026, with FDA clearance and Phase III initiation for obesity by end of Q3 2026. Why it matters: ASC30 could differentiate itself as a once-daily oral option in a GLP-1 market dominated by injectable therapies, potentially expanding the oral segment beyond current oral semaglutide. What to watch next: Q3 2026 topline readout and whether the efficacy and safety profile supports a best-in-class narrative against established injectables. Source
Brii Bio Presents HBV Functional Cure Data at APASL 2026
Brii Bio shared cross-study analysis at the Asian Pacific Association for the Study of the Liver conference showing that 90% of participants (38 of 41) who achieved HBsAg loss maintained HBV DNA below the lower limit of quantification off-treatment, with no ALT flares observed among those with HBsAg rebound. The analysis covered participants treated with pegylated interferon alfa with or without the company's BRII-179 immunotherapeutic or elebsiran siRNA. Both candidates hold Breakthrough Therapy Designation from China's NMPA, and the company estimates hepatitis B affects 254 million people globally with 87 million chronically infected in China alone. Why it matters: The high rate of sustained virologic control off-treatment addresses a significant unmet need in HBV management, and the absence of ALT flares suggests a favorable safety profile for these immunotherapeutic approaches. What to watch next: Durability of HBsAg loss in longer follow-up and whether the combination regimens demonstrate clear superiority over pegylated interferon monotherapy. Source
Watchlist
None. The tape is light with no additional weaker items qualifying for surveillance during this 48-hour window.